Petros G. Nikolinakos, MD, (“Dr. Nik”), is University Cancer & Blood Center’s managing partner. He also serves as the director and principal investigator of UCBC’s clinical research program which conducts numerous trials involving novel targeted therapies, immunotherapies, and breakthrough cancer treatments. Dr. Nikolinakos is a clinical Associate Professor at the University of Georgia and Augusta University and is a recipient of the 2013 ASCO Clinical Trials Participation Award.
Dr. Nikolinakos is board-certified in medical oncology, hematology, and internal medicine. He joined UCBC in September 2009 after completing fellowship in Hematology and Oncology at the NCI designated MD Anderson Cancer Center in Houston, Texas where he conducted basic science as well as clinical and translational research. Prior to this, he was a resident and Chief Medical Resident at Chicago’s Cook County Hospital.
An author and cancer researcher, Dr. Nikolinakos has published on a variety of clinical and basic science cancer topics in The New England Journal of Medicine, Journal of Cancer Research, Journal of Clinical Oncology, Oncogene, American Journal of Hematology, Journal of Clinical Investigation, and the Journal of Thoracic Oncology. His numerous abstracts have been presented at the American Society of Clinical Oncology (ASCO) and the American Association for Cancer Research (AACR).
Dr. Nikolinakos’ passion is driven by the bonds he builds with his patients and their families and the enjoyment he holds in helping others. Dr. Nikolinakos enjoys traveling to Greece and finds a special interest in wildlife photography.
BOARDS:
Georgia Society of Clinical Oncology, 2022–present
Board for Georgia Core, 2018–present
Clinical Governance Council For Piedmont Healthcare, 2018-present
Medical Staff Quality Committee for Piedmont Athens Regional Medical Center,r 2015–present
RESEARCH/PUBLICATIONS:
Martini R, Chen Y, Jenkins BD, Elhussin IA, Cheng E, Hoda SA, Ginter PS, Hanover J, Zeidan RB, Oppong JK, Adjei EK, Jibril A, Chitale D, Bensenhaver JM, Awuah B, Bekele M, Abebe E, Kyei I, Aitpillah FS, Adinku MO, Ankomah K, Osei-Bonsu EB, Nathansan SD, Jackson L, Jiagge E, Petersen LF, Proctor E, Nikolinakos P, Gyan KK, Yates C, Kittles R, Newman LA, Davis MB. Investigation of triple-negative breast cancer risk alleles in an International African-enriched cohort. Sci Rep. 2021 Apr 29;11(1):9247. doi: 10.1038/s41598-021-88613-w. PMID: 33927264; PMCID: PMC8085076.
Weaver R, Traina T, Dalenc F, Aftimos P, Lynce F, Diab S, Cortés J, O’Shaughnessy J, Diéras V, Ferrario C, Schmid P, Carey LA, Gianni L, Piccart MJ, Loibl S, Goldenberg DM, Hong Q, Olivo MS, Itri LM, Rugo HS; ASCENT Clinical Trial Investigators. Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer. N Engl J Med. 2021 Apr 22;384(16):1529-1541. doi: 10.1056/NEJMoa2028485. PMID: 33882206.
Liu Y, Zhao W, Cheng R, Harris BN, Murrow JR, Hodgson J, Egan M, Bankey A, Nikolinakos PG, Laver T, Meichner K, Mao L. Fundamentals of integrated ferrohydrodynamic cell separation in circulating tumor cell isolation. Lab Chip. 2021 Mar 15. doi: 10.1039/d1lc00119a. Epub ahead of print. PMID: 33720269.
Choueiri TK, Powles T, Burotto M, Escudier B, Bourlon MT, Zurawski B, Oyervides Juárez VM, Hsieh JJ, Basso U, Shah AY, Suárez C, Hamzaj A, Goh JC, Barrios C, Richardet M, Porta C, Kowalyszyn R, Feregrino JP, Żołnierek J, Pook D, Kessler ER, Tomita Y, Mizuno R, Bedke J, Zhang J, Maurer MA, Simsek B, Ejzykowicz F, Schwab GM, Apolo AB, Motzer RJ; CheckMate 9ER Investigators. Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N Engl J Med. 2021 Mar 4;384(9):829-841. doi: 10.1056/NEJMoa2026982. PMID: 33657295.
Nilsson MB, Robichaux J, Herynk MH, Cascone T, Le X, Elamin Y, Patel S, Zhang F, Xu L, Hu L, Diao L, Shen L, He J, Yu X, Nikolinakos P, Saintigny P, Fang B, Girard L, Wang J, Minna JD, Wistuba II, Heymach JV. Altered Regulation of HIF-1α in Naive- and Drug-Resistant EGFR-Mutant NSCLC: Implications for a Vascular Endothelial Growth Factor-Dependent Phenotype. J Thorac Oncol. 2021 Mar;16(3):439-451. doi: 10.1016/j.jtho.2020.11.022. Epub 2020 Dec 9. PMID: 33309987.
Malhotra J, Nikolinakos P, Leal T, Lehman J, Morgensztern D, Patel JD, Wrangle JM, Curigliano G, Greillier L, Johnson ML, Ready N, Robinet G, Lally S, Maag D, Valenzuela R, Blot V, Besse B. A Phase 1-2 Study of Rovalpituzumab Tesirine in Combination With Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Extensive-Stage SCLC. J Thorac Oncol. 2021 Feb 27:S1556-0864(21)01745-7. doi: 10.1016/j.jtho.2021.02.022. Epub ahead of print. PMID: 33652156.
Johnston PB, Cashen AF, Nikolinakos PG, Beaven AW, Barta SK, Bhat G, Hasal SJ, De Vos S, Oki Y, Deng C, Foss FM. Belinostat in combination with standard cyclophosphamide, doxorubicin, vincristine and prednisone as first-line treatment for patients with newly diagnosed peripheral T-cell lymphoma. Exp Hematol Oncol. 2021 Feb 18;10(1):15. doi: 10.1186/s40164-021-00203-8. PMID: 33602316; PMCID: PMC7893947.
Goldman JW, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D, Statsenko G, Hochmair MJ, Özgüroğlu M, Ji JH, Garassino MC, Voitko O, Poltoratskiy A, Ponce S, Verderame F, Havel L, Bondarenko I, Każarnowicz A, Losonczy G, Conev NV, Armstrong J, Byrne N, Thiyagarajah P, Jiang H, Paz-Ares L; CASPIAN investigators. Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2021 Jan;22(1):51-65. doi: 10.1016/S1470-2045(20)30539-8. Epub 2020 Dec 4. PMID: 33285097.
Yang JC, Camidge DR, Yang CT, Zhou J, Guo R, Chiu CH, Chang GC, Shiah HS, Chen Y, Wang CC, Berz D, Su WC, Yang N, Wang Z, Fang J, Chen J, Nikolinakos P, Lu Y, Pan H, Maniam A, Bazhenova L, Shirai K, Jahanzeb M, Willis M, Masood N, Chowhan N, Hsia TC, Jian H, Lu S. Safety, Efficacy, and Pharmacokinetics of Almonertinib (HS-10296) in Pretreated Patients With EGFR-Mutated Advanced NSCLC: A Multicenter, Open-label, Phase 1 Trial. J Thorac Oncol. 2020 Dec;15(12):1907-1918. doi: 10.1016/j.jtho.2020.09.001. Epub 2020 Sep 9. PMID: 32916310.
Waterhouse DM, Garon EB, Chandler J, McCleod M, Hussein M, Jotte R, Horn L, Daniel DB, Keogh G, Creelan B, Einhorn LH, Baker J, Kasbari S, Nikolinakos P, Babu S, Couture F, Leighl NB, Reynolds C, Blumenschein G Jr, Gunuganti V, Li A, Aanur N, Spigel DR. Continuous Versus 1-Year Fixed-Duration Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer: CheckMate 153. J Clin Oncol. 2020 Nov 20;38(33):3863-3873. doi: 10.1200/JCO.20.00131. Epub 2020 Sep 10. PMID: 32910710; PMCID: PMC7676888.
Wu YL, Tsuboi M, He J, John T, Grohe C, Majem M, Goldman JW, Laktionov K, Kim SW, Kato T, Vu HV, Lu S, Lee KY, Akewanlop C, Yu CJ, de Marinis F, Bonanno L, Domine M, Shepherd FA, Zeng L, Hodge R, Atasoy A, Rukazenkov Y, Herbst RS; ADAURA Investigators. Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer. N Engl J Med. 2020 Oct 29;383(18):1711-1723. doi: 10.1056/NEJMoa2027071. Epub 2020 Sep 19. PMID: 32955177.
Paz-Ares L, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D, Statsenko G, Hochmair MJ, Özgüroğlu M, Ji JH, Voitko O, Poltoratskiy A, Ponce S, Verderame F, Havel L, Bondarenko I, Kazarnowicz A, Losonczy G, Conev NV, Armstrong J, Byrne N, Shire N, Jiang H, Goldman JW; CASPIAN investigators. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet. 2019 Nov 23;394(10212):1929-1939. doi: 10.1016/S0140-6736(19)32222-6. Epub 2019 Oct 4. PMID: 31590988
Weiss JM, Csoszi T, Maglakelidze M, Hoyer RJ, Beck JT, Domine Gomez M, Lowczak A, Aljumaily R, Rocha Lima CM, Boccia RV, Hanna W, Nikolinakos P, Chiu VK, Owonikoko TK, Schuster SR, Hussein MA, Richards DA, Sawrycki P, Bulat I, Hamm JT, Hart LL, Adler S, Antal JM, Lai AY, Sorrentino JA, Yang Z, Malik RK, Morris SR, Roberts PJ, Dragnev KH; G1T28-02 Study Group. Myelopreservation with the CDK4/6 inhibitor trilaciclib in patients with small-cell lung cancer receiving first-line chemotherapy: a phase Ib/randomized phase II trial. Ann Oncol. 2019 Oct 1;30(10):1613-1621. doi: 10.1093/annonc/mdz278. PMID: 31504118; PMCID: PMC6857609.
Zhao W, Liu Y, Jenkins BD, Cheng R, Harris BN, Zhang W, Xie J, Murrow JR, Hodgson J, Egan M, Bankey A, Nikolinakos PG, Ali HY, Meichner K, Newman LA, Davis MB, Mao L. Tumor antigen-independent and cell size variation-inclusive enrichment of viable circulating tumor cells. Lab Chip. 2019 May 14;19(10):1860-1876. doi: 10.1039/c9lc00210c. PMID: 31041975; PMCID: PMC6590080.
Jenkins BD, Martini RN, Hire R, Brown A, Bennett B, Brown I, Howerth EW, Egan M, Hodgson J, Yates C, Kittles R, Chitale D, Ali H, Nathanson D, Nikolinakos P, Newman L, Monteil M, Davis MB. Atypical Chemokine Receptor 1 (DARC/ACKR1) in Breast Tumors Is Associated with Survival, Circulating Chemokines, Tumor-Infiltrating Immune Cells, and African Ancestry. Cancer Epidemiol Biomarkers Prev. 2019 Apr;28(4):690-700. doi: 10.1158/1055-9965.EPI-18-0955. PMID: 30944146; PMCID: PMC6450416.
Drilon A, Fu S, Patel MR, Fakih M, Wang D, Olszanski AJ, Morgensztern D, Liu SV, Cho BC, Bazhenova L, Rodriguez CP, Doebele RC, Wozniak A, Reckamp KL, Seery T, Nikolinakos P, Hu Z, Oliver JW, Trone D, McArthur K, Patel R, Multani PS, Ahn MJ. A Phase I/Ib Trial of the VEGFR-Sparing Multikinase RET Inhibitor RXDX-105. Cancer Discov. 2019 Mar;9(3):384-395. doi: 10.1158/2159-8290.CD-18-0839. Epub 2018 Nov 28. PMID: 30487236; PMCID: PMC6397691.
Schrock AB, Zhu VW, Hsieh WS, Madison R, Creelan B, Silberberg J, Costin D, Bharne A, Bonta I, Bosemani T, Nikolinakos P, Ross JS, Miller VA, Ali SM, Klempner SJ, Ou SI. Receptor Tyrosine Kinase Fusions and BRAF Kinase Fusions are Rare but Actionable Resistance Mechanisms to EGFR Tyrosine Kinase Inhibitors. J Thorac Oncol. 2018 Sep;13(9):1312-1323. doi: 10.1016/j.jtho.2018.05.027. Epub 2018 Jun 5. PMID: 29883838.
Pietrantonio F, Di Nicolantonio F, Schrock AB, Lee J, Morano F, Fucà G, Nikolinakos P, Drilon A, Hechtman JF, Christiansen J, Gowen K, Frampton GM, Gasparini P, Rossini D, Gigliotti C, Kim ST, Prisciandaro M, Hodgson J, Zaniboni A, Chiu VK, Milione M, Patel R, Miller V, Bardelli A, Novara L, Wang L, Pupa SM, Sozzi G, Ross J, Di Bartolomeo M, Bertotti A, Ali S, Trusolino L, Falcone A, de Braud F, Cremolini C. RET fusions in a small subset of advanced colorectal cancers at risk of being neglected. Ann Oncol. 2018 Jun 1;29(6):1394-1401. doi: 10.1093/annonc/mdy090. PMID: 29538669.
Waterhouse D, Horn L, Reynolds C, Spigel D, Chandler J, Mekhail T, Mohamed M, Creelan B, Blankstein KB, Nikolinakos P, McCleod MJ, Li A, Oukessou A, Agrawal S, Aanur N. Safety profile of nivolumab administered as 30-min infusion: analysis of data from CheckMate 153. Cancer Chemother Pharmacol. 2018 Apr;81(4):679-686. doi: 10.1007/s00280-018-3527-6. Epub 2018 Feb 13. PMID: 29442139.
Dirix LY, Takacs I, Jerusalem G, Nikolinakos P, Arkenau HT, Forero-Torres A, Boccia R, Lippman ME, Somer R, Smakal M, Emens LA, Hrinczenko B, Edenfield W, Gurtler J, von Heydebreck A, Grote HJ, Chin K, Hamilton EP. Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study. Breast Cancer Res Treat. 2018 Feb;167(3):671-686. doi: 10.1007/s10549-017-4537-5. Epub 2017 Oct 23. PMID: 29063313; PMCID: PMC5807460.
Sawas A, Farber CM, Schreeder MT, Khalil MY, Mahadevan D, Deng C, Amengual JE, Nikolinakos PG, Kolesar JM, Kuhn JG, Sportelli P, Miskin HP, O’Connor OA. A phase 1/2 trial of ublituximab, a novel anti-CD20 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma or chronic lymphocytic leukaemia previously exposed to rituximab. Br J Haematol. 2017 Apr;177(2):243-253. doi: 10.1111/bjh.14534. Epub 2017 Feb 21. PMID: 28220479; PMCID: PMC5412890.
Lanman RB, Mortimer SA, Zill OA, Sebisanovic D, Lopez R, Blau S, Collisson EA, Divers SG, Hoon DS, Kopetz ES, Lee J, Nikolinakos PG, Baca AM, Kermani BG, Eltoukhy H, Talasaz A. Analytical and Clinical Validation of a Digital Sequencing Panel for Quantitative, Highly Accurate Evaluation of Cell-Free Circulating Tumor DNA. PLoS One. 2015 Oct 16;10(10):e0140712. doi: 10.1371/journal.pone.0140712. PMID: 26474073; PMCID: PMC4608804.
Klempner SJ, Bazhenova LA, Braiteh FS, Nikolinakos PG, Gowen K, Cervantes CM, Chmielecki J, Greenbowe JR, Ross JS, Stephens PJ, Miller VA, Ali SM, Ou SH. Emergence of RET rearrangement co-existing with activated EGFR mutation in EGFR-mutated NSCLC patients who had progressed on first- or second-generation EGFR TKI. Lung Cancer. 2015 Sep;89(3):357-9. doi: 10.1016/j.lungcan.2015.06.021. Epub 2015 Jun 29. PMID: 26187428.
Tabernero J, Yoshino T, Cohn AL, Obermannova R, Bodoky G, Garcia-Carbonero R, Ciuleanu TE, Portnoy DC, Van Cutsem E, Grothey A, Prausová J, Garcia-Alfonso P, Yamazaki K, Clingan PR, Lonardi S, Kim TW, Simms L, Chang SC, Nasroulah F; RAISE Study Investigators. Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study. Lancet Oncol. 2015 May;16(5):499-508. doi: 10.1016/S1470-2045(15)70127-0. Epub 2015 Apr 12. Erratum in: Lancet Oncol. 2015 Jun;16(6):e262. PMID: 25877855.
Zelnak AB, Nikolinakos P, Srinivasiah J, Jonas W, Pippas A, Liu Y, Li X, Torres M, O’Regan RM; Georgia Center for Oncology Research and Education. High pathologic complete response in Her2-positive, early-stage breast cancer to a novel nonanthracycline neoadjuvant chemotherapy. Clin Breast Cancer. 2015 Feb;15(1):31-6. doi: 10.1016/j.clbc.2014.06.004. Epub 2014 Jun 24. PMID: 25065563.
Zinner RG, Obasaju CK, Spigel DR, Weaver RW, Beck JT, Waterhouse DM, Modiano MR, Hrinczenko B, Nikolinakos PG, Liu J, Koustenis AG, Winfree KB, Melemed SA, Guba SC, Ortuzar WI, Desaiah D, Treat JA, Govindan R, Ross HJ. PRONOUNCE: randomized, open-label, phase III study of first-line pemetrexed + carboplatin followed by maintenance pemetrexed versus paclitaxel + carboplatin + bevacizumab followed by maintenance bevacizumab in patients ith advanced nonsquamous non-small-cell lung cancer. J Thorac Oncol. 2015 Jan;10(1):134-42. doi: 10.1097/JTO.0000000000000366. PMID: 25371077; PMCID: PMC4276572.
Xu L, Nilsson MB, Saintigny P, Cascone T, Herynk MH, Du Z, Nikolinakos PG, Yang Y, Prudkin L, Liu D, Lee JJ, Johnson FM, Wong KK, Girard L, Gazdar AF, Minna JD, Kurie JM, Wistuba II, Heymach JV. Epidermal growth factor receptor regulates MET levels and invasiveness through hypoxia-inducible factor-1alpha in non-small cell lung cancer cells. Oncogene. 2010 May 6;29(18):2616-27. doi: 10.1038/onc.2010.16. Epub 2010 Feb 15. PMID: 20154724; PMCID: PMC3378055.
Nikolinakos PG, Altorki N, Yankelevitz D, Tran HT, Yan S, Rajagopalan D, Bordogna W, Ottesen LH, Heymach JV. Plasma cytokine and angiogenic factor profiling identifies markers associated with tumor shrinkage in early-stage non-small cell lung cancer patients treated with pazopanib. Cancer Res. 2010 Mar 15;70(6):2171-9. doi: 10.1158/0008-5472.CAN-09-2533. Epub 2010 Mar 9. PMID: 20215520; PMCID: PMC4512950.
Kim WY, Perera S, Zhou B, Carretero J, Yeh JJ, Heathcote SA, Jackson AL, Nikolinakos P, Ospina B, Naumov G, Brandstetter KA, Weigman VJ, Zaghlul S, Hayes DN, Padera RF, Heymach JV, Kung AL, Sharpless NE, Kaelin WG Jr, Wong KK. HIF2alpha cooperates with RAS to promote lung tumorigenesis in mice. J Clin Invest. 2009 Aug;119(8):2160-70. doi: 10.1172/jci38443. PMID: 19662677; PMCID: PMC2719950.
Nikolinakos P, Heymach JV. The tyrosine kinase inhibitor cediranib for non-small cell lung cancer and other thoracic malignancies. J Thorac Oncol. 2008 Jun;3(6 Suppl 2):S131-4. doi: 10.1097/JTO.0b013e318174e910. PMID: 18520296.
ABSTRACTS:
Cho, Y. M., Anderson, E. W., Guevara, S., Miyara, S. J., Iqbal, A., Aronsohn, J., Molmenti, E. P., Mumford, J. M., Keber, B., Zonouzi-Zadeh, F., Ha, Y., Nikolinakos, P. G., & Flickinger, B. (2021). Upadacitinib as novel treatment for rheumatoid arthritis with T-cell granular lymphocytic leukemia: A case report and narrative review. Journal of Clinical Rheumatology and Immunology, 1–9. https://doi.org/10.1142/s2661341722720026
Liu Y, Zhao W, Cheng R, Hodgson J, Egan M, Pope CNC, Nikolinakos PG, Mao L. Simultaneous biochemical and functional phenotyping of single circulating tumor cells using ultrahigh throughput and recovery microfluidic devices. Lab Chip. 2021 Sep 14;21(18):3583-3597. doi: 10.1039/d1lc00454a. PMID: 34346469.
Liu Y, Zhao W, Cheng R, Puig A, Hodgson J, Egan M, Cooper Pope CN, Nikolinakos PG, Mao L. Label-free inertial-ferrohydrodynamic cell separation with high throughput and resolution. Lab Chip. 2021 Jul 13;21(14):2738-2750. doi: 10.1039/d1lc00282a. PMID: 34018527.
David Michael Waterhouse, Leora Horn, Craig H. Reynolds, David R. Spigel, Jason Claud Chandler,Tarek Mekhail, Mohamed K. Mohamed, Ben C. Creelan, Kenneth Bruce Blankstein, Petros Nikolinakos, Michael McCleod, Ang Li, Ian M. Waxman, Nivedita Aanur, Shruti Agrawal. Safety profile of nivolumab administered as 30-minute (min) infusion: Analysis of data from CheckMate 153 (abstr 165497)
Lee S. Schwartzberg, MD; Kurt W. Tauer, MD; Robert C. Hermann, MD; Petros G. Nikolinakos, MD; Arthur C. Houts, PhD. Phase I/II Study of Neoadjuvant Carboplatin, Eribulin Mesylate and Trastuzumab (ECH) for Operable HER2 Positive (HER2+) Breast Cancer. J Clin Oncol 31, 2013 (suppl; abstr TPS659)
Petros Nikolinakos, N. Altorki, M. Guarino, H. Tran, D. Rajagopalan, S. Swann, W. Bordogna, L. Ottesen, D. Yankelevitz, J.V. Heymach. Analyses of plasma cytokine/angiogenic factors (C/AFs) profile during preoperative treatment with pazopanib (GW786034) in early-stage non-small cell lung cancer. J Clin Oncol 26: 2008 (May 20 suppl; abstr 7568) ASCO.
Lauren Averett Byers, Meera Nanjundan, Luc Girard, Kevin Coombes, Yang Xie, Michael Peyton, Sunny Zachariah, Stephanie Weber, Doris Siwak, Petros Nikolinakos, Gordon Mills, John Minna, and John Heymach. Reverse-phase protein array (RPPA) profiling of response to taxanes and epidermal growth factor receptor (EGFR) inhibitors identifies an inverse correlation between markers of sensitivity to docetaxel and erlotinib in non-small cell lung cancer lines. AACR Meeting Abstracts, Apr 2008; 2008: 3937.
Tina Cascone, Petros Nikolinakos, Li Xu, Matthew Herynk, Monique Nilsson, and John Heymach. Differential regulation hypoxia inducible factor (HIF)-1 and -2 in human NSCLC cell lines bearing wild type and mutated EGFR. AACR Meeting Abstracts, Apr 2008; 2008: 2039.
Byers, Lauren Averett, Nanjundan, Meera, Girard, Luc, Coombes, Kevin, Xie, Yang, Peyton, Michael, Ma, Yao, Zachariah, Sunny, Nikolinakos, Petros, Minna, John, Heymach, John. Reverse-phase protein array (RPPA) profile of non-small cell lung cancer lines identifies tumor signatures for sensitivity and resistance to chemotherapy and targeted agents. AACR Meeting Abstracts, 2007: B178e
Caio Max S. Rocha Lima, Patrick J. Roberts, Victor M. Priego, Stephen G. Divers, Melanie B. Thomas, Ralph V. Boccia, Katie Stabler, Elizabeth Andrews, Rajesh K. Malik, Raid Aljumaily, John Turner Hamm, Vi Kien Chiu, Donald A. Richards, Petros Nikolinakos, Maen A. Hussein, Steven Robert Schuster, Robert John Hoyer, Geoffrey Shapiro, Konstantin H. Dragnev, Taofeek Kunle Owonikoko. Trilaciclib (G1T28), a cyclin dependent kinase 4/6 inhibitor, in combination with etoposide and carboplatin (EP) for extensive stage small cell lung cancer (ES-SCLC): Phase 1b results (2017 ASCO Abstract 194528)
Sarina Anne Piha-Paul, James A. Knost, Petros Nikolinakos, Lee Steven Schwartzberg, Denise A. Yardley, Eric Daniel Slosberg, Barinder Kang, Theresa White, Claudia Lebedinsky; The University of Texas MD Anderson Cancer Center, Houston, TX; Illinois Cancer Care, Peoria, IL; University Cancer and Blood Center, Athens, GA; The West Clinic, Memphis, TN; Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville, TN; Novartis Oncology, East Hanover, NJ; Novartis Pharmaceuticals, East Hanover, NJ; Novartis Pharmaceuticals Corporation, East Hanover, NJ; Colorectal Cancer (CRC) Cohort Analysis of Patients Treated with Buparlisib in a Disctinctive Tissue-Agnostic Trial Model for Molecularly Pre-Selected Tumors (2015 Journal of Clinical Oncology, Abstract 140219)
Lindsay Carol Overton, Christopher L. Corless, Manish Agrawal, Vasily J. Assikis, Nancy L. Beegle, Sibel Blau, Marc Chernoff, Stephen G. Divers, David H. Henry, Petros Nikolinakos, Colleen Oliver, Eric Scott Schaefer, Frederick M. Schnell, Dennis Slater, Daniel Lewis Spitz, Vicki Tosher, Robert J. Green; Impact of next-generation sequencing (NGS) on treatment decision in the community oncology setting (2014 Journal of Clinical Oncology, Abstract 128879)
Owen A. O’Connor, MD, PhD, Changchun Deng, MD, PhD, Jennifer E Amengual, MD, Marshall Schreeder, MD, Daruka Mahadevan, MD, Mazen Y. Khalil, MD, Petros Nikolinakos, MD, Ahmed Sawas, MD, Jasmine Zain, MD, Molly Patterson, MSW, Sean Clark-Garvey, MPH, Michelle Mackenzie, RN, Emily K. Pauli, PharmD, Kathy Cutter, RN, Marnie Brotherton, RN, Amber Moon, RN, Jamie Hodgson, CRCC, Christen N. Cooper, RN, Peter Sportelli, Hari Miskin and Charles M. Farber, MD, PhD. Results of a Phase I Dose-Escalation Trial with Ublituximab (TG-1101), a Novel Anti-CD20 Monoclonal Antibody (mAb) for Patients with Rituximab Relapsed/Refractory Lymphoma (2013 Journal of Clinical Oncology, Abstract 8575)
Nikolinakos P, Lippman SM. Two Genomic Strategies in Non-Small Cell Lung Cancer Prognosis. Abstracts in Hematology & Oncology. 2007; 10(3):4-7.
Reilly BM, Clarke P, Nikolinakos P. Clinical problem-solving. Easy to see but hard to find. N Engl J Med. 2003 Jan 2;348(1):59-64. doi: 10.1056/NEJMcps022093. PMID: 12510044.
Koduri PR, Singa P, Nikolinakos P. Autoimmune hemolytic anemia in patients infected with human immunodeficiency virus-1. Am J Hematol. 2002 Jun;70(2):174-6. doi: 10.1002/ajh.10096. PMID: 12116960.
Shekarappa RJ, Nikolinakos P, Bansidhar T, Sistoza E, Smith J. Photo quiz. Back rash. Am Fam Physician. 1999 Sep 1;60(3):927-8. PMID: 10498117.
